drugset / Trial / NCT05392257
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial is an investigator-initiated multicenter, open, prospective clinical study in order to explore the efficacy and safety of rituximab plus zanubrutinib and lenalidomide in relapsed and refractory diffuse large B cell lymphoma.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |
Indications
No indication recorded.